David A. Baker

Consumer Services

Health Technology

Profile

David A.
Baker is the founder who founded Promentis Pharmaceuticals, Inc. in 2007 and held the title of Director.
He received a doctorate degree from Arizona State University in 1999 and an undergraduate degree from Montana State University in 1992.

Former positions of David A. Baker

Companies	Position	End
Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.	Founder	-

See the detail of David A. Baker's experience

Training of David A. Baker

Arizona State University	Doctorate Degree
Montana State University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David A. Baker's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.	Health Technology